ERBB2 and cancer: TIMER returned a good prognosis for a high level of TRPA1 expression in the following immune cells: B cells for BRCA-Her2, LUAD, SKCM and THYM cancers; T CD8+ cells from ACC and SKCM cancer; T CD4+ cells for CESC; macrophages from THYM cancer; neutrophils from CHOL, SKCM and UMV cancer; and dendritic cells in SKCM and THYM.